Join the Tirzepatide group to help and get support from people like you.
Tirzepatide News
GLP-1 RAs May Reduce Risk for Some Obesity-Linked Cancers Versus Insulin in T2D
THURSDAY, July 11, 2024 – For patients with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for 10 of 13 obesity-associated cancers...
Significantly More Weight Loss Seen With Tirzepatide Versus Semaglutide
MONDAY, July 8, 2024 – Tirzepatide is associated with significantly greater weight loss than semaglutide for adults with overweight or obesity, according to a study published online July 8 in JAMA...
ADA: Tirzepatide Reduces Apnea-Hypopnea Index in Moderate-to-Severe OSA
WEDNESDAY, June 26, 2024 – Tirzepatide reduces the apnea-hypopnea index (AHI) among individuals with moderate-to-severe obstructive sleep apnea and obesity, according to a study published online...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for...
Most Slow Responders to Tirzepatide Do Lose Clinically Meaningful Weight
TUESDAY, May 14, 2024 – Among slow responders to tirzepatide treatment at week 12, 90 percent went on to achieve clinically meaningful weight reduction (≥5 percent) by week 72, according to a study p...
Aspiration Pneumonia Risk Increased for GLP-1 RA Users Undergoing Endoscopy
FRIDAY, April 12, 2024 – Patients using glucagon-like peptide 1 receptor agonists (GLP-1 RAs) undergoing endoscopic procedures have an increased risk for aspiration pneumonia, according to a study...
Tirzepatide Improves 24-Hour BP in Obesity-Related Hypertension
WEDNESDAY, Feb. 7, 2024 – For patients with obesity and hypertension, tirzepatide improves 24-hour blood pressure (BP), according to a research letter published online Feb. 5 in Hypertension. James...
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Continuing Tirzepatide Leads to Maintenance of Weight Reduction
MONDAY, Dec. 11, 2023 – Withdrawing tirzepatide after 36 weeks is associated with regain of lost weight, while weight loss is maintained with continued treatment, according to a study published...
Tirzepatide Tied to Substantial Additional Weight Loss After Lifestyle Intervention
WEDNESDAY, Nov. 8, 2023 – Tirzepatide provides substantial additional reduction in body weight in participants who already achieved ≥5.0 percent weight reduction with an intensive lifestyle i...
FDA Approves Zepbound (tirzepatide) for Chronic Weight Management
INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity t...
Wegovy, Ozempic Help Folks Lose Weight, But How?
TUESDAY, Oct. 10, 2023 – As many doctors and patients hail the advent of weight-loss drugs like Ozempic and Wegovy as the perfect fix for obesity, some experts are urging caution. The drugs are not...
Reductions Seen in HbA1c, Body Weight With Once-Weekly Tirzepatide
FRIDAY, Oct. 6, 2023 – For patients with inadequately controlled type 2 diabetes, once-weekly subcutaneous injections of tirzepatide yield reductions in hemoglobin A1c (HbA1c) and body weight...
Tirzepatide Bests Semaglutide for Patients With Type 2 Diabetes
THURSDAY, Oct. 5, 2023 – Tirzepatide is superior to semaglutide for both blood sugar control and weight loss among people with type 2 diabetes, according to research presented at the European...
Diabetes Drug Maker, Sues Over Compounded Versions of Mounjaro
WEDNESDAY, Sept. 20, 2023 – Another diabetes drug maker is taking legal action against businesses in several states, alleging that they’re “fraudulently claiming” that their compounded products are t...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Diabetes, Type 2